The White House is reportedly leaning toward naming former deputy U.S. Surgeon General Erica Schwartz as the next director of the Centers for Disease Control and Prevention, potentially handing her one of the most scrutinized jobs in Washington. If nominated, Schwartz would still have to survive a Senate confirmation before she could take the reins at the CDC.
According to The Washington Post, three people who spoke on condition of anonymity said the administration is tilting in Schwartz’s direction, although no formal announcement has been made. A later report from Reuters echoed that the White House was leaning her way and underscored that any official nomination would kick off a politically charged confirmation fight.
Who Is Erica Schwartz?
Schwartz is a physician and retired Public Health Service rear admiral who served as deputy U.S. surgeon general from March 2019 to April 2021 and previously led health programs for the U.S. Coast Guard, according to regulatory filings. Butterfly Network’s SEC filing lays out her medical and public health credentials and notes that she has recently sat on boards in the private health sector, experience that is likely to get a close look from senators.
Political Stakes And Confirmation
Any CDC chief needs Senate approval, and the administration has repeatedly delayed naming a permanent director while it searches for someone who can survive that gantlet. Axios reported in March that the holdup reflects worries about finding a candidate acceptable to both the Health Secretary and skeptical senators. The Washington Post has detailed how vaccine politics and shifts in key advisory panels have turned what used to be a technical appointment into a full-contact political sport.
Agency Turmoil Raises Stakes
The reported move toward Schwartz comes after a bruising stretch for the CDC, including the contested ouster of Director Susan Monarez and the resignation of other senior officials, developments that critics say have hollowed out the agency’s leadership bench. AP reported that those departures followed clashes over vaccine policy and reorganization efforts at HHS and the CDC. Hoodline also tracked Monarez’s removal and the public health uproar surrounding the agency in Atlanta.
What To Watch Next
For now, there is no formal nomination and no official word from the White House. If Schwartz is tapped, senators are likely to dig into her government record, her views on hot-button issues like vaccines and pandemic preparedness, and her ties to private health companies. Her board memberships and corporate filings are almost certain to be waved around in hearing rooms, while public health groups press any nominee on scientific independence. Reuters noted that officials who discussed the deliberations did so anonymously and said the timing for a final decision remains unclear.
